Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
COPY THAT!
This will go huge soon!! Same pattern as $PDSB before it went into the teens.
Pat Mayo presented this at the recent Global NASH Congress.
If you look at pages 22-25, you'll see what AI-POWR has projected for the 225mg cohort.
By the way, even the 75mg results were exceptional, and way more than good enough to move on to Phase IIb, which they plan to open in Q4.
In just 28 days at the low dose, CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
https://12ewye24eigk3g5kwa2dxjzm-wpengine.netdna-ssl.com/wp-content/uploads/2021/04/4thGlobal_NASH_Congress_Draft_20Apr2021_FINAL-1.pdf
June 2021 Hepa Biz Presentation
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
HEPA AI-POWR
https://hepionpharma.com/ai-powr/
Tackling Chronic Liver Disease - CRV431 Mechanism of Action
Best of luck and max returns to your investments!
Copy that make sure you guys enjoy your Sunday I’m at the beach getting some rays listening to the waves crash and watching my girlfriend engaging in a yoga class!
$PDSB
HEPA #5 now, and climbing rapidly.
An effective anti fibrosis drug, absolute game changer
thelion.com/
$HEPA
I hope they both do well. CRV431 75mg is showing less side effects and near the same efficacy as MDGL drug I believe we will see HEPA 225mg data for CRV431 come out soon. HEPA is the only molecule targeting anti fibrotic scaring the other companies are taking a different approach. I like the upside of HEPA at 160 million cap and close to 120 million in cash their phase 2B NASH trial coming up with AI platform to help the company execute more efficiently saving time and money and targeting the right patient population. NASh conference coming up at the end of June!
Hence I'll be looking closely at these projections for the 225mg dose when top line data is presented. If they are on target, that will provide quite a measure of validation of the AI-POWR platform
We talk about all the indications for which CRV431 appears to have tremendous potential, and some of them have enormous global treatment markets, including NASH itself at tens of billions of dollars and with a huge CAGR, but let's not lose sight of the fact that there is currently no approved treatment for NASH, so with a fat score in the 225mg cohort, the house could soon be rockin'!!
HEPA CRV431 in Nash Phase 2A Preliminary Conclusions:
1. Reduction transaminases at 28 days what MDGL took 3 months to achieve signals early efficacy for HEPA CRV431 in F2/F3 Nash subjects.
2. HEPA CRV431 predicts reductions in serum alanine transaminase.
3. Trial simulations with HEPA's AIPOWR platform predict & suggest greater efficacy at 150mg and 225mg dose levels!
4. Bioinformatics with AI-POWR trademarked reveal reveal significant interactions with with collagen regulating genes.
5. Confirmation of these effects will be fully evaluated using the 225mg cohort and the final genomic & lipidomic, and biomarker data for a full simulation of the Phase2b Trial for NASH.
HEPA Tackling Nash & Chronic Liver Disease - CRV431 Mechanism of Action.
ALL good buddy PDSB has a shelf offering for a 100 million in June 2020. They haven't issued more shares to the float yet! They do these kind of things for strategic reasons & flexibility usually if there are people looking to acquire a company or be acquired. Also if HEPA did do another offering it wouldn't be for a while. This company has so much going for it's fabulous. The Shelf's are an insurance policy.
Those who don't know the most basic stuff, like the difference between authorized shares and issued shares, really shouldn't be trading stocks at all, but then they won't be around for very long, so!
https://seekingalpha.com/news/3593924-pds-biotech-files-for-100m-mixed-shelf
There's almost no retail to wrest shares from. There are 76m shares out. >95% institutional ownership.
No filings were submitted for ~70% of the 64m shares bought at the November and February offerings, meaning the vast majority was concealed.
Before institutions bought 64m shares at those offerings, there were 12m shares out, with 3m in the public float. So, direct holders had ~9m shares of that, and tutes got 64m at the offerings, which possibly left ~3m for retail then. The only reason there had been any volume at all here was because the effective float had been bloated by abusive naked short selling.
We talk about all the indications for which CRV431 appears to have tremendous potential, and some of them have enormous global treatment markets, including NASH itself at tens of billions of dollars and with a huge CAGR, but let's not lose sight of the fact that there is currently no approved treatment for NASH, so with a fat score in the 225mg cohort, the house could soon be rockin'!!
By the way, some competitors' greatly inferior NASH drugs are being valued in the billions. Just a 1B MC for Hepion makes for $13.12 a share, and CRV431 is going to eventually treat many other indications, some with treatment markets in the many tens of billions.
To put into perspective HEPA NASH market is 10x greater than what PDSB is trying to capture with their Cancer & Covid Indications. There is so much more coming down the pipeline with HEPA. Know what you own add at these levels and you will be rewarded greatly imo
$HEPA
Thanks!
Here's the program for the upcoming International Liver Congress meeting. If Hepion presents Phase IIa top line data for CRV431 in NASH there, it will almost certainly be on that Saturday.
https://program.m-anage.com/ilc2021/en-GB/PublicProgram/Index?pProgramGrade=Scientific&pHideLogin=False&pHidePersonal=False&pShowPrivate=False
Last year, Hepion chose an International Liver Congress meeting in August to present P1 results, with announcement on the same day they gave it.
Major expansion is coming, with some super fat value drivers on the way, including the addition of a molecule to the pipeline, planned P2 clinical studies for CRV431 in multiple myeloma & hepatoma, and perhaps IPF, plus so much more. Nash Market in the tens of Billion by 2029 nearing 90 Billion!!
We're looking at one hell of an exciting time, and it's gonna make for one hell of an exciting ride. Lock those shares up, and get strapped in!
The + Directional Indicator is at 35.52, the -DI is 9.41, and ADX is 23.92, just a hair's breadth from going above 25, which is where we want to see it, as that tells us the trend is nice and strong. It'll go over 25 soon, probably on Monday, and I think it will move a lot higher, especially with that overbought stochastic being rock steady.
Trend is so important!
HEPA up 25% This week when I first alerted at $1.70 Massive Reversal in the charts new highs coming HEPA.
$HEPA
Weekly wedge breakout. First Target $5.50 and high Target Price $13.00
Value drivers on the way, including the addition of a molecule to the pipeline, planned P2 clinical studies for CRV431 in multiple myeloma & hepatoma, and perhaps IPF, plus so much more.
We're looking at one hell of an exciting time, and it's gonna make for one hell of an exciting ride. Lock those shares up, and get strapped in!
HEPA SweepCast alerted:
With Unusual Options Activity Alerted on $7.5 P Expiring: 09-17-2021 worth 174K
Weekly wedge breakout. First Target $5.50 and high Target Price $13.00
CRV431s best known quality at present is that it significantly reduces liver fibrosis with literally zero safety concerns...I think this is from last year...“Researchers of semaglutide (Ozempic, Novo Nordisk) shared data in 2020 from a very large phase 2b trial in 320 patients treated for 18 months at the recent AASLD meeting, showing positive results on NASH resolution. However, it didn’t hit the endpoint of fibrosis improvement. Further analysis is underway to better understand this result.”
HEPA's CRV431 Good morning Todd Hobbs.
When Todd Hobbs was the vice president and cheief medical officer at Novo Nordisk he was essential in getting Ozempic approved and to market as treatment for diabetes and cardiovascular. diseases. Additionally he was just as critically involved in the preclinical and clinical trials of Ozempic for treatment of Nash and ita intial partnership with Gilead in 2020 for the same.
Most importantly Todd Hobbs was at Novo Nordisk in March 2020 when Ozempic study on Nash met all end points in Nash 2B Study with exception of reduction of liver Fibrosis Hobbs Left his high level job at 188 Billion Novo Nordisk in December 2020 and began with a little biotech company called Hepion Pharmaceuticals.
HEPA just happened to have CRV431 which has shown it is extremely effective in reducing liver fibrosis with ZERO safety concerns. After that backdrop anyone believe he left Novo Nordisk for HEPA is a coincidence that CRV431 is backed up by every single trial performed best anti-fibrotic in the clinic!!!
Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/
Added more $HEPA at (which has begun to reverse), consider the facts:
(a) According to yahoo finance Book value $4.20 a share and below avg insider purchase price (both rare privileges)
b) HEPA has extremely experienced (100+ years cumulative), intelligent, proven, and dare I say very down to earth executives that are fully aligned with shareholder value ( options & open-market buys).
(c) From our current awareness of the science, CRV is an extremely safe and potentially very effective treatment for NASH (tens of billion $ market with no SOC)
(d) Due to cash value & the treatment being almost as safe as water, severe downside seems capped.
(e) CATALYSTS: Phase 2a this month showing potential early signs of efficacy 2B planned later this year & potential partnerships in other indications.
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action.
Fabulous James Welcome & have a fabulous weekend.
$HEPA
Where is everybody Have a great weekend folks!
Frank is just getting started. The man has a drawerful of cards to play. This is his baby, from the beginning, and he's got it all mapped out. When you bet on little pre-clinical and clinical stage biotechs in the very earlygoing, look at breadth & depth of potential of the pipeline, with a kickass platform.
$PDSB
I attempted to IHUB said check back in 30 days you want to get on as Moderator and I will join as soon as I can.
$HEPA
Fat ass Hal has gotten taken to cleaners on quality small cap bios that have got explosive growth in their DNA like HEPA.
HEPA the signals couldn’t be clearer this has 10x written all over it.
HEPA Setting up for a move!
HEPA BUY AND HODL Diamond Hands Laser eyes.
Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million n cash
HEPA Hepion Pharmaceuticals 170 Million market cap 120 million n cash
$HEPA
I feel really bad for people who sold or got there stop losses taken out they just got robbed straight gaffled up!
Long & Strong Know what you own people 90-95% of the shares are locked after the two offerings the company is loaded with cash 120 million burning about 19 million a year.
One of my top picks of the year same trading pattern as PDSB its like almost in lockstop and then a 600% move up this year
Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million n cash
HEPA Hepion Pharmaceuticals 170 Million market cap 120 million n cash
$HEPA
Welcome Bertllc!
$HEPA
Just loaded my second 25k block this morning and a 5k block 55k added on the dip today. I feel bad taking candy from a baby you know what I mean Ruffierruff
$HEPA
Exactly I just added a 25k block a few minutes ago and will keep adding to my stash!
$HEPA
For those asking for price target. Have a look at this article and set your own price.
The global non-alcoholic steatohepatitis (NASH) drugs market is expected to reach US $84 Billion in 2029, growing at a CAGR of 39.13%, for the duration spanning 2018-2029. The factors such as rising healthcare expenditure, increasing pharmaceutical R&D expenditure, surging diabetic population, escalating obese population, unmet medical needs and sedentary lifestyles are expected to drive the growth of the market.
Non-Alcoholic Steatohepatitis (NASH) Drugs Market :
The global non-alcoholic steatohepatitis (NASH) drugs market is expected to reach US$84.34 billion in 2029, growing at a CAGR of 39.13%, for the duration spanning 2018-2029. The factors such as rising healthcare expenditure, increasing pharmaceutical R&D expenditure, surging diabetic population, escalating obese population, unmet medical needs and sedentary lifestyles are expected to drive the growth of the market. However, the market growth would be challenged by lethargic drug approval process, high treatment cost and less definitive diagnostic methods for NASH/NAFLD. A few notable trends include surging market penetration for NASH major drugs, increasing prevalence of NASH, progressing NASH diagnosis methods and biomarkers, NASH pipeline drugs under development and growth in e-commerce pharmaceutical products sales.
https://www.marketwatch.com/press-release/non-alcoholic-steatohepatitis-nash-drugs-market-in-depth-industry-analysis-on-size-cost-structure-and-prominent-key-players-analysis-2021-03-17
Pat Mayo presented this at the recent Global NASH Congress. If you look at pages 22-25, you'll see what AI-POWR has projected for the 225mg cohort.
By the way, even the HEPA CRV431 75mg results were exceptional, and way more than good enough to move on to Phase IIb, which they plan to open in Q4.
In just 28 days at the low dose, CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish!
https://12ewye24eigk3g5kwa2dxjzm-wpengine.netdna-ssl.com/wp-content/uploads/2021/04/4thGlobal_NASH_Congress_Draft_20Apr2021_FINAL-1.pdf
I'll be looking closely at these projections for the 225mg dose when top line data is presented. If they are on target, that will provide quite a measure of validation of the AI-POWR platform
We talk about all the indications for which CRV431 appears to have tremendous potential, and some of them have enormous global treatment markets, including NASH itself at tens of billions of dollars and with a huge CAGR, but let's not lose sight of the fact that there is currently no approved treatment for NASH, so with a fat score in the 225mg cohort, the house could soon be rockin'!!
The institutional ownership is actually far greater than 90%, but the number only takes into account what was reported in filings. ~70% of the 44m shares institutions bought at the February offering were not reported in SEC filings, and ditto for the 20m shares at the November offering.
There are 76m shares out, and of the 12m before the two offerings.
Only 3m was publicly floated.
HEPA there is literally a few million shares floating around or less!
MDGL 1.7 Billion market cap
ARKO 1 Billion market cap
HEPA 170 Million market cap 116 million in cash. company burning under 5 million a quarter about 20 million a year
https://giphy.com/gifs/television-arena-political-hzrvwvnbgIV6E
$HEPA
Nash valuation that are in line with MDGL and AKRO coming soon for HEPA
Pat Mayo presented this at the recent Global NASH Congress. If you look at pages 22-25, you'll see what AI-POWR has projected for the 225mg cohort.
By the way, even the 75mg results were exceptional, and way more than good enough to move on to Phase IIb, which they plan to open in Q4.
In just 28 days at the low dose, CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish,
I'll be looking closely at these projections for the 225mg dose when top line data is presented. If they are on target, that will provide quite a measure of validation of the AI-POWR platform!
https://12ewye24eigk3g5kwa2dxjzm-wpengine.netdna-ssl.com/wp-content/uploads/2021/04/4thGlobal_NASH_Congress_Draft_20Apr2021_FINAL-1.pdf
Conclusion: some competitors' greatly inferior NASH drugs are being valued in the billions. Just a 1B MC for Hepion makes for $13.12 a share, and CRV431 is going to eventually treat many other indications, some with treatment markets in the many tens of billions
AKRO 1 Billion market cap
MDGL 1.7 Billion market cap
HEPA 170 million dollar market cap. 120 Million in cash Burning 5 million a quarter very low burn rate.
https://giphy.com/gifs/television-arena-political-hzrvwvnbgIV6E
$HEPA
Just the beginning!
Don't sell for peanuts this is a rare gem that has asymmetrical upside from these levels. Know what you own.
HEPA 10:00+ is coming sooner than later for a fair evaluation.
HEPA $13.00 price per share gives it a Billion dollar valuation in line with its NASH peers AKRO & MDGL
074 - Hepion Tackles NASH in P2 with Cyclophilin Inhibitor | Interview with HEPA CEO Robert Foster:
3rd home!
HEPA Asymmetrical upside
shorties playing fear tactics walking down after-hours. Squeeze um We going lot higher.
$13.00 = 1 Billion market cap.
Remember MDGL has 1.8 Billion market cap HEPA data is just as good on the 75mg once oral pill we have data on the 150mg and 225mg once a day oral pills which will blow MDGL out of the water.
This team at HEPA is experienced 100 years of experience with the molecule there working on CRV431 has a broad array of indications in the pipeline. Management at HEPA got a blockbuster FDA approved drug recently with the company founder who is the founder and CEO of HEPA. There addition of Hobbs from novo nordisk as the companies new chief medical officer and the board of directors pedigree is next level. And don’t forget the AI -Powr platform to help them save time and money and result with high efficacy results for their NASH and other drugs
HEPA has multiple catalyst coming up know what you own! This is a potential 10 bagger next 6-12 months
MDGL 1.8 billion market cap 280 million in cash
HEPA 160 million market cap 120 million in cash
$HEPA
Couple things to point out here!
1.Russell reconstitution officially takes place on the 24th, but related ETF's are taking on Hepion shares well ahead of that, and it will amount to millions...
2.Chairman of the Board, Gary Jacob, is not just a business guy, he's one hell of a biochemist, and you can bet he has a solid grasp of everything that's going on with Hepion.
He's a key player here!
His background goes way beyond what you ordinarily see on the BOD of little R&D biotechs. You might see those with his research background on Scientific Advisory Boards, but they wouldn't have a fraction of the business expertise he's got.
Hepion has the whole package, with this guy!!
3. I think this might have something to do with Todd Hobbs coming to Hepion. It was published in December. Hobbs' primary focus has always been on diabetes, and I have said many times that there's a blockbuster reason for him leaving his position as Vice President, Chief Medical Officer at Novo Nordisk, a USD 190B global pharmaceutical behemoth, after nearly 17 years there, to come to tiny Hepion.
4. I believe we'll be hearing about CRV431 in the treatment of diabetes, as it has the highest known potency of any reported cyclophilin inhibitor known, by a wide margin...
https://pubmed.ncbi.nlm.nih.gov/32970961/
5. Other big things in the pipeline as well!!
"STATISTICALLY MORE PROFOUND ANTI-HCV INHIBITION"!
This has partnership written all over it, yet Gilead and Hepion steadfastly refuse to acknowledge it. The silence is deafening!!
Results were published on May 20th, following rigorous peer review of this NIAID-supported study, yet Hepion & Gilead have held back press release for nearly 3 weeks.
Gilead's product is FDA approved, and clinical studies evaluating the potential to safely enhance clinical efficacy of FDA approved products present a potentially RAPID PATH TO COMMERCIALIZATION!
6. AS for NASH
The International Liver Congress, here's the schedule for the four-day event, June 23-26.
If Hepion presents top line Phase IIa results for CRV431 in NASH there, it would almost certainly be on the 25th or 26th, as you can see.
By the way, it was an International Liver Congress event that they chose to present P1 results at last year, and they did not announce it until the morning of the presentation..
7. There are dozens of indications we've so far seen that HEPA's CRV431 could Play a vital role in treating.
Here there's an application for treating acne.
The other day it was gum disease.
All sorts of cancers.
Diabetes.
NASH.
Heart disease.
IPF
Kidney fibrosis.[
We could go on and on.
It's Ridiculous.
CRV431 is a non-immunosuppressive, pan-cyclophilin inhibitor, and it is the most potent cyclophilin inhibitor known, by a huge margin.
Anyhow, the results of this study were just published the other day, and the treatment market is obviously gigantic:
'Electricity-producing Staphylococcus epidermidis counteracts Cutibacterium acnes'
https://www.nature.com/articles/s41598-021-91398-7
8. And what I love is a thinly traded shares floating in a BIO stock with multiple blockbuster indications in the pipeline:
95% of real shares are owned by institutions, with about 70% of that ownership hidden, in other words no SEC filings were ever made.
Arbitrary trading activity is almost non-existent, and certainly has zero influence on stock movement.
There are 76m shares out, with tutes having bought 64m of them at the back-to-back November & February offerings!
Don't sell for peanuts this will be over $10.00+ sooner than later!
https://giphy.com/gifs/television-arena-political-hzrvwvnbgIV6E
HEPA 160 million market cap 120 Million in cash Burning 5 million a quarter.
$HEPA
Chomp Chomp!!
HEPA CRV431 in Nash Phase 2A Preliminary Conclusions:
1. Reduction transaminases at 28 days what MDGL took 3 months to achieve signals early efficacy for HEPA CRV431 in F2/F3 Nash subjects.
2. HEPA CRV431 predicts reductions in serum alanine transaminase.
3. Trial simulations with HEPA's AIPOWR platform predict & suggest greater efficacy at 150mg and 225mg dose levels!
4. Bioinformatics with AI-POWR trademarked reveal reveal significant interactions with with collagen regulating genes.
5. Confirmation of these effects will be fully evaluated using the 225mg cohort and the final genomic & lipidomic, and biomarker data for a full simulation of the Phase2b Trial for NASH.
HEPA Tackling Nash & Chronic Liver Disease - CRV431 Mechanism of Action.
Also been accumulating the last few days! In the $14.00 range & heavy on the options! Let’s go!
BB
BTW Just reading that right now let’s go Sir Branson
Great read by the way!
So happy I doubled by stash in the teens last month
$SPCE
The global non-alcoholic steatohepatitis (NASH) drugs market is expected to reach $84 Billion in 2029, growing at a CAGR of 39.13%, for the duration spanning 2018-2029
International Nash day June 10th!
NASH as a Global Public Health Challenge
NASH and Liver Cancer
NASH and Obesity
Pediatric NASH
NASH and Diabetes
Beyond the Biopsy: Innovations in Diagnostics
NASH in Lean Individuals
NASH: A Conversation in the Black Community
https://www.international-nash-day.com
145 Million market cap 120 million in cash Phase 2B Nash 2021 Hepa is very undervalued at these levels.
MDGL 2 Billion market cap Phase 2 (Hepa got the safer drug & better data)
By the way, even the 75mg results were exceptional, and way more than good enough to move on to Phase IIb, which they plan to open in Q4.
In just 28 days at the low dose, CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish,
Projections for the 225mg dose when top line data is presented. If they are on target, that will provide quite a measure of validation of the AI-POWR platform
https://hepionpharma.com/ai-powr/
The very strong upward trend continues, and will do so for quite a long while to come!
$HEPA
Wealth Creator!
Happy Thursday Ladies & Gentlemen!
This stock defies gravity & is one of the best performing stocks in the last 12 months! Great board to be apart of!
The very strong upward trend continues, and will do so for quite a long while to come...
$PDSB
Thanks for the 411.
Primed to head higher along with the biotech sector.
Loading up!
Only a matter of time.
Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/
HEPA Tackling Nash & Chronic Liver Disease - CRV431 Mechanism of Action.
Copy that Porterhouse!
Hepa June 2021 Biz Presentation
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
Hepa CRV431 Nash Drug
Solid move Ruff their trying to shake every loose share as humanely and as Algoly possible!
My shares are lock and loaded GTC sky high across a half a dozen accounts!
Can launch at a moments notice although I like the synchronized grind up.
Patience prevails watering the garden and about to take a swim while the bots and dirty operators play with themselves. Adding meticulously the last few weeks will keep buying more as I’m allocating 10% of my options earnings to Hepa lots of fire power at my disposable! This is my small cap bio pick of the year!
$HEPA
$20.00+ Stock masquerading in the 2.00’s
Nash players 13 billion dollar market. No FDA approved drugs to date!
MDGL 1.8 Billion market cap
HEPA 150 Million market cap 120 million in cash burning 5 million a quarter very low burn rate! Strong safety and efficacy data.
$HEPA
It's show time people fortunes will be made new millionaires will be made. You can make book on that!
Legendary run in the making! 10-20x ROI potential from these levels.
Buy Hold for real life changing gains and prosper.
RIP shorts!
https://giphy.com/gifs/memecandy-H767DLijQ3XCBa5fgR
$HEPA
Great charity all the way around !
$CLOV
Thanks buddy there where so many people in maui you couldn't find a car to rent wasn't that relaxing but It was nice to get out and find a pad the girlfriend approved of. I plan on buying more property with my Hepa investment Long term hold really reminds me so much of PDSB & BCRX when I got in very early around the 2.00 range. Have a powerful day
$HEPA
Copy that chainweight your probably looking at seven figure returns with that kind of investment!
$Hepa
winner winner chicken dinner sit back and enjoy the show and watch your money grow.
PDSB JUNE 2021 Biz Presentation.
https://www.pdsbiotech.com/images/pdf/presentation/2021/june/PDSB_Corporate_Overview_-_June_7_FINAL_1.pdf
PDSB website.
https://www.pdsbiotech.com/
52 week low 1.12
52 week high 13.48
Love the stair stepping action & being invested in the space sector Branson & other key execs from Disney are why I'm here.
$PSCE
I have been accumulating. And will keep adding. Trading is eerily similar to PDSB when it was a couple bucks. This company has so much upside for Nash & other indications. Great to see you onboard.
Hepa CRV431 Showing better results than MDGLwith less side effects at 28 days then MDGL Nash drug 1.8 Billion market cap..
HEPA AI powered platform saves the company time and money on their clinical trials:
Multi-omics analyses – 25,000 data points per patient
Identify biomarkers that predict response to CRV431
Optimize and de-risk clinical trials through patient matching to CRV431 – precision medicine.
The company said it has conducted nine individual animal studies of fibrosis and found consistent and statistically significant antifibrotic effects of CRV431 in every one of these studies. Antifibrotic activity has also been observed in previously reported studies conducted by an independent U.K. laboratory that studied explanted liver and lung tissues taken from human donors. Taken together, these animal and human tissue experiments give the company a "great deal of confidence" that CRV431 has beneficial antifibrotic effects that are expected to be borne out clinically.
Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action.
I will be donating 10% of my gains on CLOV to saint Judes anyone else feel like giving back its a great charity
$CLOV